formaldehyde has been researched along with Encephalitis, Japanese B in 9 studies
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy
| Excerpt | Relevance | Reference |
|---|---|---|
| "A single dose of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) was shown to be immunogenic and well tolerated when given either as a booster to formalin-inactivated Japanese encephalitis (JE)-vaccine (mouse brain-derived vaccine [MBDV])-primed 2-5-year-olds, or as a primary vaccination to JE-vaccine-naïve 12-24-month-old toddlers in Thailand." | 2.82 | Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children. ( Boaz, M; Bouckenooghe, A; Chokephaibulkit, K; Feroldi, E; Pancharoen, C; Sirivichayakul, C; Thisyakorn, U, 2016) |
| "P20778, an Indian strain of Japanese encephalitis virus (JEV) obtained from Vellore in the Southern India, was grown in Vero cells cultured on microcarriers in a spinner flask." | 1.32 | Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. ( Appaiahgari, MB; Vrati, S, 2004) |
| "These included herpes simplex, varicella-zoster, cytomegalo, subacute sclerosing panencephalitis, progressive multifocal leukoencephalopathy, Japanese B encephalitis, measles, acute hemorrhagic conjunctivitis, Lassa and Korean hemorrhagic fever." | 1.27 | Detection of viral antigens in formalin-fixed specimens by enzyme treatment. ( Aoyama, Y; Hondo, R; Kurata, T; McCormick, JB; Oda, A; Sato, S, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chokephaibulkit, K | 1 |
| Sirivichayakul, C | 1 |
| Thisyakorn, U | 1 |
| Pancharoen, C | 1 |
| Boaz, M | 1 |
| Bouckenooghe, A | 1 |
| Feroldi, E | 1 |
| Appaiahgari, MB | 1 |
| Vrati, S | 1 |
| Abe, M | 1 |
| Shiosaki, K | 1 |
| Hammar, L | 1 |
| Sonoda, K | 1 |
| Xing, L | 1 |
| Kuzuhara, S | 1 |
| Kino, Y | 1 |
| Holland Cheng, R | 1 |
| Kurata, T | 1 |
| Hondo, R | 1 |
| Sato, S | 1 |
| Oda, A | 1 |
| Aoyama, Y | 1 |
| McCormick, JB | 1 |
| Darwish, MA | 3 |
| Hammon, WM | 3 |
| Inoue, YK | 1 |
| Nishibe, Y | 1 |
| Smith, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children[NCT00621764] | Phase 2 | 300 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, >39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, >3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.~2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, >39˚C; Headache, Malaise, and Myalgia, Prevents activities." (NCT00621764)
Timeframe: Day 0 up to Day 14 post-vaccination
| Intervention | Participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site Pain (N=50,50,0,0) | Grade 3 Injection site Pain (N=50,50,0,0) | Injection site Tenderness (N=0,0,101,99) | Grade 3 Injection site Tenderness (N=0,0,101,99) | Injection site Erythema (N=50,50,101,99) | Grade 3 Injection site Erythema (N=50,50,101,99) | Injection site Swelling (N=50,50,101,99) | Grade 3 Swelling (N=50,50,101,99) | Fever (N=50,50,101,99) | Grade 3 Fever (N=50,50,101,99) | Headache (N=50,50,0,0) | Grade 3 Headache (N=50,50,0,0) | Malaise (N=50,50,0,0) | Grade 3 Malaise (N=50,50,0,0) | Myalgia (N=50,50,0,0) | Grade 3 Myalgia (N=50,50,0,0) | Vomiting (N=0,0,101,99) | Grade 3 Vomiting (N=0,0,101,99) | Crying abnormal (N=0,0,101,99) | Grade 3 Crying abnormal (N=0,0,101,99) | Drowsiness (N=0,0,101,99) | Grade 3 Drowsiness (N=0,0,101,99) | Appetite lost (N=0,0,101,99) | Grade 3 Appetite lost (N=0,0,101,99) | Irritability (N=0,0,101,99) | Grade 3 Irritability (N=0,0,101,99) | |
| Hepatitis A/JE-CV (Group 2) | 13 | 0 | NA | NA | 9 | 0 | 5 | 0 | 8 | 0 | 7 | 0 | 13 | 0 | 8 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Hepatitis A/JE-CV (Group 4) | NA | NA | 19 | 0 | 16 | 0 | 8 | 0 | 18 | 0 | NA | NA | NA | NA | NA | NA | 21 | 0 | 20 | 0 | 13 | 0 | 32 | 2 | 24 | 0 |
| JE-CV/Hepatitis A (Group 1) | 15 | 0 | NA | NA | 7 | 0 | 4 | 0 | 8 | 1 | 7 | 0 | 15 | 0 | 14 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| JE-CV/Hepatitis A (Group 3) | NA | NA | 43 | 0 | 23 | 0 | 6 | 0 | 14 | 0 | NA | NA | NA | NA | NA | NA | 21 | 1 | 24 | 0 | 22 | 0 | 28 | 0 | 32 | 0 |
"12 to 24 months - Injection site: Tenderness, Erythema, and Swelling; Systemic reactions: Fever, Vomiting, Crying Abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3: Tenderness, Cries if limb is moved; Erythema and Swelling, ≥5 cm; Fever, >39.5˚C; Vomiting, ≥ 6 times/day; Abnormal crying, >3 hours; Drowsiness, Sleeping often; Appetite lost, Refuses ≥3 feeds/meals; Irritability, Inconsolable.~2 to 5 years - Injection site: Pain, Erythema, and Swelling; Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3: Pain, Incapacitating; Erythema and Swelling, ≥5 cm; Fever, >39˚C; Headache, Malaise, and Myalgia, Prevents activities." (NCT00621764)
Timeframe: Day 0 up to Day 14 post-vaccination
| Intervention | Participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site Pain (N=48,51,0,0) | Grade 3 Injection site Pain (N=48,51,0,0) | Injection site Tenderness (N=0,0,100,98) | Grade 3 Injection site Tenderness (N=0,0,100,98) | Injection site Erythema (N=48,51,100,98) | Grade 3 Injection site Erythema (N=48,51,100,98) | Injection site Swelling (N=48,51,100,98) | Grade 3 Swelling (N=48,51,100,98) | Fever (N=48,51,100,98) | Grade 3 Fever (N=48,51,100,98) | Headache (N=48,51,0,0) | Grade 3 Headache (N=48,51,0,0) | Malaise (N=48,51,0,0) | Grade 3 Malaise (N=48,51,0,0) | Myalgia (N=48,51,0,0) | Grade 3 Myalgia (N=48,51,0,0) | Vomiting (N=0,0,100,98) | Grade 3 Vomiting (N=0,0,100,98) | Crying abnormal (N=0,0,100,98) | Grade 3 Crying abnormal (N=0,0,100,98) | Drowsiness (N=0,0,100,98) | Grade 3 Drowsiness (N=0,0,100,98) | Appetite lost (N=0,0,100,98) | Grade 3 Appetite lost (N=0,0,100,98) | Irritability (N=0,0,100,98) | Grade 3 Irritability (N=0,0,100,98) | |
| Hepatitis A/JE-CV (Group 2) | 9 | 0 | NA | NA | 7 | 0 | 4 | 0 | 14 | 0 | 14 | 0 | 18 | 0 | 10 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Hepatitis A/JE-CV (Group 4) | NA | NA | 20 | 0 | 22 | 0 | 11 | 0 | 28 | 2 | NA | NA | NA | NA | NA | NA | 19 | 1 | 21 | 0 | 14 | 0 | 24 | 1 | 24 | 0 |
| JE-CV/Hepatitis A (Group 1) | 15 | 0 | NA | NA | 8 | 0 | 8 | 0 | 5 | 1 | 7 | 0 | 13 | 0 | 7 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| JE-CV/Hepatitis A (Group 3) | NA | NA | 35 | 1 | 23 | 0 | 6 | 0 | 23 | 1 | NA | NA | NA | NA | NA | NA | 23 | 1 | 19 | 2 | 17 | 0 | 26 | 2 | 22 | 1 |
JE virus neutralizing antibody measurement was assessed by plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer < 10 (1/dil) and post-vaccination titer ≥ 10 (1/dil), or participants with pre-vaccination titer ≥ 10 (1/dil) and 4-fold increase from pre- to post-vaccination. (NCT00621764)
Timeframe: Day 0 (pre-vaccination) and Day 28 after final vaccination
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Homologous virus (N=49,48,83,88) | Genotype I (N=49,48,81,91) | Genotype II (N=49,48,81,91) | Genotype III (N=49,48,81,93) | Genotype IV (N=49,48,81,90) | |
| Hepatitis A/JE-CV (Group 2) | 95.8 | 93.8 | 93.8 | 91.7 | 91.7 |
| Hepatitis A/JE-CV (Group 4) | 93.2 | 95.6 | 95.6 | 94.6 | 65.6 |
| JE-CV/Hepatitis A (Group 1) | 89.8 | 83.7 | 83.7 | 87.8 | 89.8 |
| JE-CV/Hepatitis A (Group 3) | 100.0 | 98.8 | 96.3 | 100.0 | 74.1 |
Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay. (NCT00621764)
Timeframe: Day 0 (pre-vaccination) up to 5 years after final vaccination
| Intervention | Titers (Geometric Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Homologous virus (pre-vaccination; N=50,50,100,94) | Homologous virus (post-vaccination; N=49,50,98,96) | Homologous virus (post-6 months; N=48,49,99,98) | Homologous virus (post-1 year; N=48,45,91,89) | Homologous virus (post-2 years; N=43,41,85,79) | Homologous virus (post-3 years; N=40,38,68,56) | Homologous virus (post-4 years; N=41,36,63,56) | Homologous virus (post-5 years; N=40,38,60,50) | Genotype I (pre-vaccination; N=50,50,97,95) | Genotype I (post-vaccination; N=49,50,96,97) | Genotype I (6-months; N=47,48,99,98) | Genotype II (pre-vaccination; N=49,50,97,95) | Genotype II (post-vaccination; N=49,50,96,97) | Genotype II (post-6 months; N=47,48,99,98) | Genotype III (pre-vaccination; N=50,50,97,97) | Genotype III (post-vaccination; N=49,50,96,97) | Genotype III (post-6 months; N=48,48,99,98) | Genotype IV (pre-vaccination; N=49,50,97,94) | Genotype IV (post-vaccination; N=49,50,96,97) | Genotype IV (post-6 months; N=47,48,99,98) | |
| Hepatitis A/JE-CV (Group 2) | 41.1 | 3722.2 | 1244.3 | 621 | 662 | 505 | 559 | 287 | 55.3 | 2116.7 | 981.0 | 33.3 | 1763.4 | 714.4 | 41.1 | 2210.4 | 645.7 | 19.7 | 874.0 | 363.4 |
| Hepatitis A/JE-CV (Group 4) | 5.15 | 167.1 | 49.8 | 49.0 | 67.1 | 90.5 | 110 | 58.2 | 5.18 | 163.1 | 52.4 | 5.20 | 126.8 | 42.4 | 5.08 | 102.1 | 20.2 | 5.00 | 18.1 | 12.6 |
| JE-CV/Hepatitis A (Group 1) | 48.6 | 1956.7 | 892.1 | 339 | 414 | 422 | 360 | 222 | 54.8 | 1015.8 | 863.5 | 46.5 | 920.6 | 581.2 | 37.6 | 1107.1 | 513.1 | 25.2 | 604.0 | 279.4 |
| JE-CV/Hepatitis A (Group 3) | 6.11 | 517.6 | 96.6 | 78.8 | 94.2 | 146 | 137 | 68.8 | 5.62 | 186.8 | 81.4 | 5.75 | 163.2 | 72.3 | 5.39 | 200.2 | 31.1 | 5.31 | 28.5 | 21.0 |
JE virus neutralizing antibody measurement was assessed by the PRNT50 assay. (NCT00621764)
Timeframe: Day 0 (pre-vaccination) and Day 28 after final vaccination
| Intervention | Titers (Geometric Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Homologous virus (pre-vaccination; N=49,48,86,90) | Homologous virus (post-vaccination; N=49,48,84,93) | Genotype I (pre-vaccination; N=49,48,83,91) | Genotype I (post-vaccination; N=49,48,82,94) | Genotype II (pre-vaccination; N=49,48,83,91) | Genotype II (post-vaccination; N=49,48,82,94) | Genotype III (pre-vaccination; N=49,48,83,93) | Genotype III (post-vaccination; N=49,48,82,94) | Genotype IV (pre-vaccination; N=49,48,83,90) | Genotype IV (post-vaccination; N=49,48,82,94) | |
| Hepatitis A/JE-CV (Group 2) | 40.6 | 3568 | 55.3 | 1988 | 34.2 | 1566 | 40.6 | 2089 | 20.0 | 829 |
| Hepatitis A/JE-CV (Group 4) | 5.08 | 167 | 5.00 | 155 | 5.00 | 121 | 5.00 | 98.2 | 5.00 | 17.0 |
| JE-CV/Hepatitis A (Group 1) | 49.5 | 1957 | 55.2 | 1016 | 46.5 | 921 | 39.2 | 1107 | 25.2 | 604 |
| JE-CV/Hepatitis A (Group 3) | 5.78 | 500 | 5.00 | 170 | 5.00 | 157 | 5.00 | 189 | 5.00 | 25.3 |
Japanese Encephalitis virus neutralizing antibody measurement was assessed by the PRNT50 assay. (NCT00621764)
Timeframe: Day 0 (pre-vaccination) up to 5 years after final vaccination
| Intervention | Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Homologous virus (pre-vaccination; N=50,50,100,94) | Homologous virus (post-vaccination; N=49,50,98,96) | Homologous virus (post-6 months; N=48,49,99,98) | Homologous virus (post-1 year; N=48,45,91,89) | Homologous virus (post-2 years; N=43,41,85,79) | Homologous virus (post-3 years; N=40,38,68,56) | Homologous virus (post-4 years; N=41,36,63,56) | Homologous virus (post-5 years; N=40,38,60,50) | Genotype I (pre-vaccination; N=50,50,97,95) | Genotype I (post-vaccination; N=49,50,96,97) | Genotype I (post-6 months; N=47,48,99,98) | Genotype II (pre-vaccination; N=49,50,97,95) | Genotype II (post-vaccination; N=49,50,96,97) | Genotype II (post-6 months; N=47,48,99,98) | Genotype III (pre-vaccination; N=50,50,97,97) | Genotype III (post-vaccination; N=49,50,96,97) | Genotype III (post-6 months; N=48,48,99,98) | Genotype IV (pre-vaccination; N=49,50,97,94) | Genotype IV (post-vaccination; N=49,50,96,97) | Genotype IV (post-6 months; N=47,48,99,98) | |
| Hepatitis A/JE-CV (Group 2) | 41 | 50 | 49 | 44 | 41 | 38 | 36 | 38 | 41 | 50 | 48 | 39 | 50 | 48 | 38 | 50 | 48 | 32 | 50 | 48 |
| Hepatitis A/JE-CV (Group 4) | 2 | 89 | 80 | 71 | 64 | 52 | 54 | 44 | 3 | 93 | 86 | 2 | 93 | 80 | 1 | 92 | 62 | 0 | 65 | 46 |
| JE-CV/Hepatitis A (Group 1) | 45 | 49 | 48 | 46 | 41 | 40 | 41 | 40 | 40 | 49 | 47 | 39 | 49 | 47 | 41 | 49 | 48 | 39 | 48 | 47 |
| JE-CV/Hepatitis A (Group 3) | 15 | 98 | 91 | 81 | 74 | 66 | 63 | 55 | 8 | 95 | 95 | 9 | 93 | 90 | 5 | 96 | 73 | 5 | 73 | 68 |
1 review available for formaldehyde and Encephalitis, Japanese B
| Article | Year |
|---|---|
Arbovirus vaccines.
Topics: Animals; Antibody Formation; Arbovirus Infections; Encephalitis, Japanese; Encephalitis, Tick-Borne; | 1969 |
1 trial available for formaldehyde and Encephalitis, Japanese B
| Article | Year |
|---|---|
Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
Topics: Child, Preschool; Cross-Over Studies; Encephalitis Virus, Japanese; Encephalitis, Japanese; Female; | 2016 |
7 other studies available for formaldehyde and Encephalitis, Japanese B
| Article | Year |
|---|---|
Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells.
Topics: Animals; Antibodies, Viral; Chlorocebus aethiops; Disinfectants; Encephalitis Viruses, Japanese; Enc | 2004 |
Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines.
Topics: Adolescent; Adult; Animals; Antibodies, Monoclonal; Antibodies, Viral; Antigens, Viral; Child; Chlor | 2006 |
Detection of viral antigens in formalin-fixed specimens by enzyme treatment.
Topics: Adolescent; Adult; Aged; Animals; Antigens, Viral; Chickenpox; Child; Conjunctivitis; Cytomegaloviru | 1983 |
Studies on Japanese B encephalitis virus vaccines from tissue culture. VI. Development of a hamster kidney tissue culture inactivated vaccine for man. 2. The characteristics of inactivation of an attenuated strain of OCT-541.
Topics: Animals; Cricetinae; Culture Techniques; Encephalitis Viruses; Encephalitis, Japanese; Formaldehyde; | 1966 |
Japanese B encephalitis virus vaccines from tissue culture. VII. Formalin inactivated Nakayama strain vaccine.
Topics: Animals; Culture Techniques; Encephalitis Viruses; Encephalitis, Japanese; Formaldehyde; Haplorhini; | 1966 |
Studies on Japanese B encephalitis virus vaccines from tissue culture. 8. Formalin inactivated OCT-wild strain vaccine.
Topics: Animals; Culture Techniques; Encephalitis Viruses; Encephalitis, Japanese; Formaldehyde; Guinea Pigs | 1966 |
The experimental production of a formalin-killed Japanese encephalitis virus vaccine from porcine kidney cell cultures.
Topics: Animals; Antibodies; Culture Techniques; Encephalitis Viruses; Encephalitis, Japanese; Formaldehyde; | 1967 |